

# Nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection

Letícia Cristina Assis

UFLA

Alexandre Alves de Castro

UFLA

João Paulo Almirão de Jesus

UTFPR

Eugenie Nepovimova

UHK

Kamil Kuca (✉ [kamil.kuca@uhk.cz](mailto:kamil.kuca@uhk.cz))

UHK

Teodorico de Castro Ramalho

UFLA

Felipe de Almeida La Porta (✉ [felipelaporta@utfpr.edu.br](mailto:felipelaporta@utfpr.edu.br))

UTFPR <https://orcid.org/0000-0003-0990-7947>

---

## Short Report

**Keywords:** SARS-CoV-2, In silico modelling, nitro derivatives of quinoline and quinoline N-oxide, Computational Design

**Posted Date:** May 29th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-32468/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

A new and more aggressive strain of coronavirus, known as SARS-CoV-2, which is highly contagious, has rapidly spread across the planet within a short period of time. Due to its high transmission rate and the significant time-space between infection and manifestation of symptoms, the WHO recently declared this a pandemic. Because of the exponentially growing number of new cases of both infections and deaths, development of new therapeutic options to help fight this pandemic is urgently needed. The target molecules of this study were the nitro derivatives of quinoline and quinoline N-oxide. Computational design at the DFT level, docking studies, and molecular dynamics methods as a well-reasoned strategy will aid in elucidating the fundamental physicochemical properties and molecular functions of a diversity of compounds, directly accelerating the process of discovering new drugs. In this study, we discovered isomers based on the nitro derivatives of quinoline and quinoline N-oxide, which are biologically active compounds and may be low-cost alternatives for the treatment of infections induced by SARS-CoV-2.

## Introduction

We are currently facing a new coronavirus disease designated as COVID-19. It started in China and has spread rapidly around the world, resulting in serious threats to international health and the economy.<sup>1,2</sup> The International Committee on the Taxonomy of Viruses denominated the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This denomination is derived from the fact that the RNA genome is approximately 82% identical to the SARS coronavirus (SARS-CoV).<sup>3</sup> In addition, the SARS-CoV-2 reveals a 79% similarity with SARS (Severe Acute Respiratory Syndrome) coronavirus and a 50% similarity with MERS (Middle Eastern Respiratory Syndrome) coronavirus.<sup>4</sup>

The crystallographic structure of SARS-CoV-2 exhibits approximately 88% sequence identity with the other two coronaviruses found in bats (bat-SLCoVZC45 and bat-SL-CoVZXC21).<sup>5</sup> For this reason, it is believed that the original host of the SARS-CoV-2 outbreak was bat-like.<sup>6</sup> Since discovery, an exponential growth in the number of cases of infections and deaths has been observed worldwide.<sup>3,7,8</sup> The World Health Organization (WHO) responded quickly to the COVID-19 threat by developing diagnostics and providing general guidance on patient monitoring, as well as up-to-date information; it also declared the outbreak a pandemic on March 11, 2020.<sup>8,9</sup>

The overall situation is progressing daily worldwide.<sup>10</sup> In order to further the development of prevention and control techniques, we must have a better comprehension of the nature of the pandemic.<sup>11,12</sup> It is important to know that SARS-CoV-2 replicates in the upper respiratory tract, and infected patients produce a multitude of virus particles which further contributes to the spread of infection.<sup>13</sup> Similar to MERS and SARS, there are no distinguishing clinical features of COVID-19, and symptoms overlap significantly with other severe acute respiratory infections.<sup>9,14-16</sup>

Clinical characterization protocols are now being collected on patients worldwide to better define the illness, in terms of its natural history, mode of transmission, clinical profiles, management, and specific

risk factors, to prevent or overcome the damaging effects of the disease.<sup>9,17</sup> What is known so far is that a significant proportion of individuals infected by COVID–19 remain asymptomatic and are thus an unbeknownst potential source of infection.<sup>18,19</sup> In symptomatic patients, the characteristic symptoms of the disease usually start less than a week after infection, and consist of fever, cough, nasal congestion, and fatigue, along with other signs of an upper respiratory tract infection.<sup>19</sup>

In early 2003, SARS-CoV was revealed as the causative agent of the emergence of SARS.<sup>20,21</sup> The SARS virus's main proteinase (Mpro), also known as SARS-CoV 3C-like protease (3CLpro), is a key enzyme responsible for the processing of viral polyproteins.<sup>21–23</sup> Together with the papain-like proteases, the Mpro is essential for the processing of polyproteins translated from the viral RNA.<sup>3,24</sup> In a structural analysis, the Mpro enzyme consists of three domains (Figure 1). Domains I (residues 8–101) and II (residues 102–184) are well-known β-barrels, which together resemble the structure of chymotrypsin. Contrarily, domain III (residues 201–306) primarily consists of α-helices. Domains II and III, respectively, are connected by a long loop (residues 185–200). Also, located in a cleft between domains I and II, the Mpro active site presents a catalytic dyad formed by the conserved Cys145 and His41 amino acid residues. Equally important is the presence of a water molecule, which is a hydrogen atom bonded to His41; it can give rise to the third component of a catalytic triad.<sup>23</sup> It was indicated that domain III of Mpro is necessary for maintaining the proteolytic activity, which takes place by holding domain II and the long loop (residues 185–200) in a catalytically favorable orientation<sup>25</sup> and/or orienting the N-terminal residues that play an important role for the catalytic activity of the enzyme.<sup>26</sup> To date, no human proteases with a similar cleavage specificity are known, suggesting that the inhibitors are unlikely to be toxic.<sup>3</sup>

Researchers worldwide are undertaking the search for a vaccine while others search for a treatment regimen targeting SARS-CoV–2. Preliminary results demonstrated the application of both chloroquine (CQ) and hydroxychloroquine (HCQ) to be promising treatments for SARS-CoV–2.<sup>30–32</sup> CQ, for instance, exhibits inhibition of the SARS-CoV-2 infection at micromolar concentrations. Both compounds are classified as 4-aminoquinoline antimalarial drugs.<sup>33</sup> However, further studies are needed to ensure the administration of these medicines is safe. Given the exposure thus far, this work aims to provide significant contributions to accelerate the discovery of novel and efficient remediation methods against the damaging effects of COVID–19.

Computational screening is now the prime focus for solving the crisis of SARS-CoV–2 infections. This is likely because such strategies reveal rational pathways for the development of fast and efficient drugs. In this regard, the combination of quantum mechanics and molecular mechanics calculations are robust tools for investigating a vast range of drug candidates, as well as identifying potential molecular targets for the sites of action of these therapeutic agents.<sup>34</sup> In this work, the nitro derivatives of quinoline (Q) and quinoline N-oxide (QO) were computationally investigated. The choice of these derivatives was predominantly based on the nitration reaction they undergo, which is characterized by the replacement of a hydrogen atom with a nitro group, and also because it is one of the most industrially used reactions and does not require the use of sophisticated equipment to be performed. This nitration reaction is

therefore extremely attractive since synthesis requires low-cost materials and simple reaction paths, and any country can implement the large-scale manufacturing process for such products. Additionally, as they may be easily synthesized, in Figure 2 was proposed an exemplified mechanism for its obtain from the Q. In this context, this research explores new therapeutic alternatives to combat the SARS-CoV-2 outbreak by utilizing computational simulations at the Density Functional Theory (DFT) level, molecular docking, and molecular dynamics methods as a well-reasoned strategy that provides insights on the physicochemical properties as well as the interaction and reactivity of these molecules as potential drug candidates.

## Results And Discussion

As a first step, we have performed DFT and TDDFT calculations for the nitro derivatives of compounds Q and QO to better understand of their electronic structure, spectroscopic properties, and chemical reactivity. Figure 3 shows the electrostatic surface potential for the optimised structure of all the nitro derivatives of Q and QO, which have screened in this *in silico* study. Hence, we can also see that the charge distribution mainly depends on the various orientations of the nitro groups - regions with negative potential (red) that act as an excellent electron acceptor - that were added to the Q and QO compounds, respectively, with the specific objective of conferring the most favorable interaction between the drug and the target. Note also that the nitro group increases the polarity of these compounds, which is an attractive characteristic for pharmacological applications.<sup>35</sup> Additionally, nitro derivatives of QO compounds, in this case, have a more polarized structure. These slight structural changes are responsible for modulating the biological activity of these compounds, which may provide new clues for an in-depth interpretation of their microscopic behavior. These theoretical findings are consistent with the molecular docking simulations performed in this study.

All compounds were also identified in terms of computed IR-active modes and UV-vis absorbance spectroscopy, as we show in Figure S1. These results can easily be used to distinguish the isomers obtained. In parallel, a comparison of the difference between the total electronic energy ( $\Delta E$ ) for the computed Q and QO isomers, presented in Table S1, suggests that both N-4-Q and N-4-QO compounds in terms of energy are more stable. Additionally, the HOMO-LUMO gaps reveal a minor difference of 4.07 to 4.31 eV for nitro derivatives of Q and of 3.11 to 3.69 eV for nitro derivatives of QO, respectively (see Table S1). In this case, a lower HOMO-LUMO gap value for QO derivatives, in principle, suggests greater reactivity for these isomers compared to Q derivatives. Figure S2 shows the shape of molecular orbitals (MOs) for all ligands studied. A detailed analysis of composition and localization of the MO reveals that the HOMO energies are, in principle, insufficient to describe the chemical behavior of these ligands. From the frontier effective-for-reaction molecular orbital (FERMO) concept, the reactions that are driven by HOMO, and those that are not, can be better explained for such compounds.<sup>36–39</sup> These findings are consistent with previous studies.<sup>38,39</sup>

To elucidate the modes through which our drug candidates interact SARS-CoV-2, the crystal structure of the Mpro of the virus in complex with 6-(ethylamino)pyridine-3-carbonitrile was downloaded for study.<sup>27</sup>

Once the enzyme had been prepared, the molecular docking protocol was initiated. In the first part of this investigation, re-docking calculations were performed using the MolAr software,<sup>29</sup> with implementation of the AutoDock Vina program.<sup>28</sup> To determine the ideal docking parameters, these re-docking calculations were performed according to the orientation and conformation adopted by the experimental co-crystallised active ligand present in the binding pocket. It is important to notice that the Mpro enzyme used in this work was found in its native form.

The small RMSD variation (0.94) obtained from the re-docking calculations, suggested that the program was able to correctly and efficiently simulate the experimental results for the respective ligands. This preliminary outcome indicated that the conformational deviation of the molecular docking technique was suitable for our purposes and that the method was highly sensitive and specific. The re-docking overlap is presented in Figure 1. To simulate the modes through which our drug candidates interact with the SARS-CoV-2 Mpro enzyme, we employed the best parameters provided by the data from the re-docking study carried out with the co-crystallised active ligand. All the computed interaction energy results are displayed in Table S2 and S3 in supplementary material.

As shown in Table S2, all the drug candidates studied (i.e., nitro derivative of Q and QO) interacted well with Mpro active site, with interaction energy values in the range of  $-4.3$  to  $-5.0$  kcal. $\text{mol}^{-1}$ , respectively. Some of the nitro-QO compounds, such as the inhibitors N-4-QO, N-9-QO, N-8-QO, together with QO, had slightly more stabilising interaction energy values than those of their corresponding nitro-quinolines (Table S2). In general, it is noteworthy that the compounds studied had a greater affinity for Mpro than the co-crystallised ligand did (the latter showing an interaction energy value of  $-3.9$  kcal mol $^{-1}$ ). In order to assess the potential of such findings, using the same protocol, docking procedures were performed with the commercial drugs CQ and HCQ, which are currently adopted for the treatment of SARS-CoV-2 infection, and their interaction energy values were found to be  $-2.8$  and  $-2.3$  kcal mol $^{-1}$ , respectively. A remarkable trend could be observed from these outcomes. Note that all of our drug candidates presented greater interaction energy values than CQ and HCQ, with a significant energy difference, of up to 2 kcal mol $^{-1}$ . Additionally, our study showed that the many of the nitro-QO compounds led to a more stabilising interaction energy in the Mpro active site. Based on these findings, we also investigated the chloroquine and hydroxychloroquine N-oxides forms (denoted as CQO and HCQO), which displayed a significant improvement in interaction energy values of  $-3.0$  and  $-3.1$  kcal mol $^{-1}$ , respectively. Interestingly, the interaction energy of HCQO was almost 1 kcal mol $^{-1}$  more stabilizing than the HCQ. This trend was deeply analyzed using molecular dynamics (MD) techniques. The influence of the N-oxide group was also investigated at different sites and through different combinations for the CQO and HCQO compounds (Table S3). According to that table, with all combinations investigated, we can observe that no improvement in interaction energy was detected for CQO. On the other hand, for HCQO, the presence of the N-oxide group at some sites led to slightly more favorable interaction energies. See table S3 for more details. Herein, our main goal was to determine whether the inhibitors studied could target the Mpro enzyme. The molecular docking pose of each drug candidate indicated that they could indeed fit accurately within the substrate-binding pocket.

In the case of SARS-CoV-2 virus Mpro enzyme, the protomer is composed of three domains, as commented previously (see Figure 1). The enzyme has a Cys145–His45 catalytic dyad, and the substrate-binding pocket is known to be located in a cleft between domains I and II.<sup>40</sup> Hence, the structural features determined from these data are important for guiding our assessment of the interaction modes of the inhibitors in the Mpro active site. As shown in Figure 4, the N-4-QO performed hydrogen bonds with all the residues and the water molecule of the catalytic triad. In fact, these specific interactions constitute one of the parameters analysed in this docking study. This same trend is not observed for inhibitor N-4-Q, suggesting that the N-oxide version of this ligand adopts a more favourable conformation which allows for its interaction with the catalytic triad, resulting in a slightly more stabilizing interaction energy. Similarly, the interactions performed by the other ligands can also be observed in Figure 4.

From the molecular docking calculations, it was possible to deduce that our drug candidates had a more stabilizing interaction energy effect than CQ and HCQ in the Mpro binding pocket. To better assess the interaction modes of our inhibitors, N-4-Q and N-4-QO were chosen as representatives of the set for MD simulations. Likewise, the same calculations were performed for CQ and HCQ and their N-oxides CQO and HCQO (see Figure S3).

Additionally, in this study, the dynamic behavior of complexes Mpro/N-4-Q, Mpro/N-4-QO, Mpro/CQ, Mpro/CQO, Mpro/HCQ, Mpro/HCQO inside the SARS-CoV-2 Mpro enzyme was investigated. Initially, we have observed that all complexes reached thermodynamic equilibrium during the 10 ns of MD simulation (see Figures S4-S9 in the supplementary material). The extracted frame, which was considered the representative conformational structure for all inhibitors throughout the MD simulation, corresponds to the average of the RMSD value. By analyzing the results of the RMSD graphs, it was observed that most of the deviations from the N-4-Q and N-4-QO structures were very small, not exceeding 0.5 Å, i.e., these ligands are well-accommodated in the SARS-CoV-2 Mpro active site according to Figures S4 and S5.

To get more insights into the intrinsic reactivity of each these ligands, in this study, we have performed the analysis of the strain effect along the MD simulation. Since these factors have a pivotal role and affect the reactivity of these ligands.<sup>41,42</sup> In the present study, the strain effect along the MD simulation can be clearly visualized by the overlap of the initial (blue) and representative (red) structures obtained after 10 ns of simulation, as shown in Figure 5. Based on Figure 5, we note that our compounds N-4-Q and N-4-QO showed a slight bending at the quinoline ring (strain), which makes this compound in principle more reactive, resulting in a small oscillation in according to the RMSD graphs (Figures S4 and S5). Importantly, this trend is essential because it indicates a low variation of strain (deformation of the ligand along simulation), reaching a stabilizing conformation more quickly. On the other hand, due to larger molecular mass and bulk of the CQ, HCQ and their corresponding oxides, there was a very higher variation of strain (Figures 5 (c–f)). We believe that this slight strain can induce a high intrinsic reactivity for these ligands.

As shown in Figure 6 (a), the N-4-Q compound performed hydrogen bond interactions with His41 (2.78 Å) and hydrophobic interactions with Leu27, Asn28, Pro39, Val42, Ile43, Cys44, Met49, Asn119, Gly143 and Gys145, respectively. These interactions are essential in inhibiting the enzymatic activity of Mpro and are in accordance with some other studies,<sup>43–45</sup> as well as the docking results of this work. By analyzing the graph of hydrogen interactions (see Figure S4), we found that the compound N-4-Q performed up to four hydrogen bond type interactions. However, there was only one effective interaction that occurred during the entire 10 ns of MD simulation, which is according to the pharmacophoric map (see Figure 6 (a)). On the other hand, the N-4-QO compound is stabilized by two hydrogen bonds with His41 (3.17 Å) and His164 (2.72 Å) and also hydrophobic interactions with Leu27, His41, Cys44, Thr45, Ser46, Met49, Cys145, His164, Met165 and Glu166, respectively, as shown in Figure 6 (b). According to Zhang and coworkers,<sup>45</sup> in the catalytic site, the residues Glu166, His41, and Gys145, respectively, are key species of the target protease. Thus, the interaction of these amino acids with inhibitors is essential for blocking the enzymatic activity of Mpro. Additionally, it is observed that the N-4-QO can make up to three bonds during the trajectory; however, occurs only one hydrogen bond in most of the entire simulation (Figure S5).

In the case of the dynamic behavior of both CQ and CQO compounds, we have observed that the structure remained stable during the 10 ns of simulation, as shown in Figures S6 and S7. In this case, the RMSD values found were around 2.5 Å. Although the RMSD deviation was high when compared to N-4-Q and N-4-QO compounds, they are coherent since the chemical structures of CQ and CQO are bulkier and had a higher molecular mass, as well as several rotational atoms. Consequently, there is a change in the conformation (Figure 6 (c) and (d)), further increasing the degrees of freedom of the inhibitors, and therefore is expected a more significant oscillation in the RMSD (see Figures S6 and S7). Through the pharmacophoric map, as shown in Figure 6 (c), it was observed that CQ performed hydrogen bond interactions with Ser46 (2.84 Å), Gln189 (2.09 Å) and Thr190 (2.67 Å) and had hydrophobic interactions with Thr25, Leu27, His41, Met49, Thr90, Ser144, Cys145, His164, Met165, Glu166, Leu167, Pro168, Ala191 and Gln192, respectively. It is essential to highlight that most of these residues are key species in catalytic activity.<sup>45</sup> Note that the CQ can perform up to three Hydrogen bonds, with only one present in the entire simulation (see also Figure S6). On the other hand, in the case of CQO, this inhibitor performed several hydrophobic interactions, specifically with the residues His41, Val42, Ser46, Leu50, Cys145, His164, Met165, Glu166, Gln189 and Thr190 (see Figure 6 (d)). These results are in accordance with the Hydrogen bond graph, since, no hydrogen bonds are observed during the 10 ns of simulation (Figure S7).

Likewise, the HCQ compound remained stable at the Mpro active site only after 8.5 ns of simulation, mainly due to many conformational changes (Figure S8), such as in relation to the amine group that underwent rotation, resulting in a more energetically favourable conformation compared to its initial chemical structure, i.e., thus decreasing the RMSD value (Figure S8 and Figure 5 (e)). However, the final configuration of CQ had less strain than HCQ. Therefore, we can speculate that the minimum strain, which is associated with a low RMSD value, is directly related to the toxicity of these compounds.

As shown in Figure 6 (e), the HCQ exhibit one hydrogen bond with Tyr54 (2.89 Å) and several hydrophobic interactions with the residues His41, Cys44, Met49, Met165, Glu166, Leu167, Pro168, Phe181, Val186, Asp187, Gln189, Thr190 and Gln192, respectively. Through the Hydrogen bond graph, it was observed that for this compound after equilibration in the active site, up to two hydrogen bonds could be accomplished (Figure S8). While the HCQO compound showed the RMSD value of around 2.5 Å, due to the structural distortions in the N-diethyl-pentane portion during the 10 ns of simulation (Figure S9). Hence, the most significant change happened approximately 6.3 ns, wherein the ligand underwent a 180° rotation, resulting in a less energetically favorable conformation compared to its initial chemical structure (Figure 5 (f)). Also, this compound performed three hydrogen bond interactions with His164 (2.61 Å) and Glu166 (1.82 Å) and hydrophobic interactions with Pro39, His41, Cys44, Ser46 Glu47, Met49, Cys145, Met165 and Gln189, respectively, as we shown in Figure 6 (f). Considering the hydrogen graph (Figure S9), the HCQO can make up to five hydrogen bonds.

From the MD simulation, we have estimated the interaction energies for all cases studied: N-4-Q (-13.65 kJ/mol), N-4-QO (-60.27 kJ/mol), CQ (-28.11 kJ/mol), CQO (-16.50 kJ/mol), HCQ (-54.88 kJ/mol), HCQO (-72.21 kJ/mol). An important outcome observed in this study is that the majority of the N-oxide compounds had an energetically more favorable affinity at the Mpro active site than their Q counterparts. These findings are consistent with the molecular docking calculations. The existence of intermolecular interactions strongly guides these trends. Note that the N-4-QO performed more hydrogen bonds than N-4-Q, as shown in Figure 6. This fact helps explain the more stabilizing interaction energy found for N-4-QO. From the pharmacophoric maps shown in Figure 6, the accomplishment of hydrogen bonds, along with the hydrophobic interactions, are key to understand the biological activity of these inhibitors.

Yet, the success of a novel drug candidate is commonly attributed to diverse factors, including their bioactivity, rich pharmacokinetic (PK) and pharmacodynamics (PD) profiles, as well as toxicity. It would be therefore of huge interest to investigate these properties in the preliminary stages to in silico design of safer and more efficient drugs. Hence, the ADMET evaluations involve sequential and iterative assessments of the efficacy, PK, PD, metabolic and toxicological properties in the model of potential drug candidates.<sup>46</sup> From the ADMET results, the theoretical parameters of toxicity (LD<sub>50</sub>) were obtained for each compound: N-4-Q (2.53 mol/kg), N-4-QO (2.56 mol/kg), CQ (2.95 mol/kg), CQO (2.68 mol/kg), HCQ (2.66 mol/kg), HCQO (2.69 mol/kg). We can observe that the parameter toxicity slightly varied from N-4-Q to N-4-QO, suggesting that the toxicity of these compounds is essentially equal. Similarly, this trend also is observed for HCQ and its corresponding N-oxide (HCQO). On the other hand, we have noticed a more significant variation for CQ and CQO compounds, indicating that CQO theoretically presents a higher level of toxicity. In addition, these molecular calculations also showed that HCQ is more toxic than CQ. Yet, this trend does not corroborate with previous experimental results.<sup>47</sup> It is essential to highlight that the molecular results obtained do not take into account the effects of the counterion and, for this reason, suggest a different trend to the experimental findings previously reported.<sup>47</sup> In particular, this divergence most-likely is related to the fact that the commercially used HCQ is a salt-based on hydroxychloroquine sulfate, while the CQ used is a salt-based on chloroquine diphosphate. It additionally

is well-known that the counterion has a substantial effect not only on its biological activity but also on the toxicity of such compounds as well.<sup>48–51</sup> Therefore, our molecular results indicate that the presence of phosphate groups contributes to increasing the toxicity of CQ in the treatment of the SARS-CoV-2 infection. Consequently, we can conclude that for the same type of salt used, it is expected CQ to be less toxic than HCQ, according to the molecular trend observed in this study.

## Conclusion

We conclude that this *in silico* study to contribute toward the rational design of new and more efficient drugs for the treatment of SARS-CoV-2 infection. Hence, the most important lesson from this structure-based study was that the QO derivatives are better inhibitors than their Q counterparts. In light of these results, we can suggest that *in vitro* and *in vivo* experiments be urgently carried out to investigate the nitro derivatives of QO further, since there is as yet no efficient treatment for this disease. Finally, we emphasise that these compounds can be easily produced on a large scale (at a low-cost), making them a promising treatment option against SARS-CoV-2 infection.

## Methods

**Datasets:** Herein, the crystal structure dataset for SARS-CoV-2 virus Mpro enzyme was obtained from the Protein Data Bank (PDB; accession ID: 5R82, resolution 1.31Å).<sup>27</sup> Then, full optimizations and frequencies of nitro derivatives of Q and QO were achieved at B3LYP level of theory with 6–31+g(d,p) basis set in the Gaussian 09 package.<sup>52</sup> For a better description of the electronic parameters, it was also performed single-point energy Time-Dependent DFT (TD-DFT) calculations at B3LYP/6–31+g(d,p) level.

**Molecular Docking:** The molecular docking was conducted with the tool AutoDock Vina (version 1.1.2),<sup>28</sup> as implemented in the MolAr (Molecular Architecture) software.<sup>29</sup> For the crystallographic Mpro structure preparation, the loop regions were rebuilt using the Modeller.<sup>53</sup> The ions and water molecules were removed from the original PDB, with the exception of water molecules that were in the Mpro active site. The addition of polar hydrogen atoms were performed according to the protonation state of the receptor at pH 7.4, by using the Chimera software.<sup>54</sup> For the docking protocol, the Mpro enzyme and the structures of Q and QO derivatives were used as receptor and ligands, respectively. The grid box was centered on the co-crystallized ligand (6-[ethylamino]pyridine-3-carbonitrile) of SARS-CoV-2 virus Mpro enzyme (5R82), and the coordinates were x = 12.053, y = -0.871 and z = 24.157, with 1 Å spacing. Docked poses were then selected on the basis of scoring functions and protein-ligand interactions. Binding interaction figures were generated using Discovery Studio 2017 R2.<sup>55</sup>

**Molecular Dynamics simulations:** In a further theoretical insight, the key docking complexes were evaluated by molecular dynamics (MD) simulation using the GROMOS54A7 all-atom force field<sup>56</sup> and performed using GROMACS 5.1 software.<sup>56,57</sup> The Mpro complexes were inserted into a 12 Å water box with the SPC solvation model, and sodium and chlorine ions were added for charges neutralization under periodic boundary conditions. The calculation of electrostatic interactions was then performed by

using the Particle Mesh Ewald method with a cut-off of 12 Å and time step of 1 fs. Initially, complexes were minimized over 5000 cycles using the steepest descent algorithm and then were submitted to a production simulation of 10 ns at 300 K and at 1 bar pressure. Atom trajectories were analyzed using Visual Molecular Dynamic (VMD, version 1.9.3).<sup>58</sup> Due to the experimental inexistence of acute toxicity data for these compounds, in principle, we also provide a theoretical estimation for the LD50 values from the using of a rat model-based admetSAR predictor, which is freely available online at <http://lmmd.ecust.edu.cn:8000/>.

## Declarations

## ACKNOWLEDGMENTS

The authors gratefully acknowledge the support from the Brazilian agencies CNPq, CAPES and FAPEMIG. We also especially grateful to the computational facilities at UFLA. It was supported by the Excellence project UHK.

## AUTHOR CONTRIBUTIONS

FAL designed the study. LCA and AAC contributed equally to this work, as well as, performed docking and dynamic molecular studies. JPAJ performed quantum chemical calculations. TCR, EN, KK and FAL conceived the project, supervised students and contributed to the review of the whole manuscript. All authors discussed the results and contributed to the final manuscript.

## COMPETING INTERESTS

All authors declare no competing interests.

## References


1. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
2. Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265–269 (2020).
3. Zhang, L. *et al.* Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. *Science (80-. ).* **3405**, eabb3405 (2020).
4. Park, M., Thwaites, R. S. & Openshaw, P. J. M. COVID-19: Lessons from SARS and MERS. *J. Immunol.* **50**, 308–311 (2020).
5. Lu, R. *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* **395**, 565–574 (2020).

6. Lu, H., Stratton, C. W. & Tang, Y.-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *Med. Virol.* **92**, 401– 402 (2020).
7. Zhang, L. & Liu, Y. Potential interventions for novel coronavirus in China: A systematic review. *Med. Virol.* **92**, 479–490 (2020).
8. Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. & de Wit, E. A Novel Coronavirus Emerging in China – Key Questions for Impact Assessment. *Engl. J. Med.* **382**, 692–694 (2020).
9. Arabi, Y. M., Murthy, S. & Webb, S. COVID-19: a novel coronavirus and a novel challenge for critical care. *Intensive Care Med.* (2020) doi:10.1007/s00134-020-05955-1.
10. Heymann, D. L. & Shindo, N. COVID-19: what is next for public health? *Lancet* **395**, 542–545 (2020).
11. Yoo, J. H. The Fight against the 2019-nCoV Outbreak: an Arduous March Has Just Begun. *Journal of Korean medical science* **35** e56 (2020).
12. Dey, S. K., Rahman, M. M., Siddiqi, U. R. & Howlader, A. Analyzing the epidemiological outbreak of COVID-19: A visual exploratory data analysis approach. *Med. Virol.* (2020) doi:10.1002/jmv.25743.
13. Chan, J. F-W. *et al.* A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* **395**, 514–523 (2020).
14. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497–506 (2020).
15. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513 (2020).
16. Arabi, Y. M. *et al.* Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. *Care Med.* **45**, 1683–1695 (2017).
17. Zhang, T. *et al.* Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. *China. Life Sci.* (2020) doi:10.1007/s11427-020-1660-2.
18. Deng, S.-Q. & Peng, H.-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. *Clin. Med.* **9**, (2020).
19. Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* **323**, 1061–1069 (2020).
20. Drosten, C. *et al.* Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *Engl. J. Med.* **348**, 1967–1976 (2003).
21. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. ( 3CL pro) Structure : Basis for Design of Anti-SARS Drugs. *Science (80-)*. **300**, 1763– 1767 (2003).
22. Kumar, V., Tan, K.-P., Wang, Y.-M., Lin, S.-W. & Liang, P.-H. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. *Med. Chem.* **24**, 3035–3042 (2016).
23. Tan, J. *et al.* pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses. *Mol. Biol.* **354**, 25–40 (2005).

24. Hilgenfeld, R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. *FEBS J.* **281**, 4085–4096 (2014).
25. Anand, K. *et al.* Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. *EMBO J.* **21**, 3213–3224 (2002).
26. Yang, H. *et al.* The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Natl. Acad. Sci. U. S. A.* **100**, 13190–13195 (2003).
27. Berman, H. M. *et al.* The Protein Data Bank. *Nucleic Acids Res.* **28**, 235–242 (2000).
28. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Comput. Chem.* **31**, 455–461 (2010).
29. Maia, E. H. B., Medaglia, L. R., da Silva, A. M. & Taranto, A. G. Molecular Architect: A User-Friendly Workflow for Virtual Screening. *ACS omega* **5**, 6628–6640 (2020).
30. Savarino, A., Di Trani, L., Donatelli, I., Cauda, R. & Cassone, A. New insights into the antiviral effects of chloroquine. *The Lancet. Infectious diseases* **6** 67–69 (2006).
31. Wang, M. *et al.* Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* **30**, 269–271 (2020).
32. Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov. Ther.* **14**, 58–60 (2020).
33. Cortopassi, W. A. *et al.* Docking studies on the binding of quinoline derivatives and hematin to plasmodium falciparum lactate dehydrogenase. *Biomol. Struct. Dyn.* **29**, 207–218 (2011).
34. La Porta, F. A. & Taft, C. A. *Emerging Research in Science and Engineering Based on Advanced Experimental and Computational Strategies*. (Springer, Cham, 2020). doi:10.1007/978-3-030-31403-3.
35. Sliwoski, G., Kothiwale, S., Meiler, J. & Lowe, E. W. Computational Methods in Drug Discovery. *Rev.* **66**, 334 LP – 395 (2014).
36. da Silva, R. R., Ramalho, T. C., Santos, J. M. & Figueroa-Villar, J. D. On the Limits of Highest-Occupied Molecular Orbital Driven Reactions: The Frontier Effective-for-Reaction Molecular Orbital Concept. *J. Phys. Chem. A* **110**, 1031– 1040 (2006).
37. La Porta, F. A., Ramalho, T. C., Santiago, R. T., Rocha, M. V. J. & da Cunha, F. Orbital Signatures as a Descriptor of Regioselectivity and Chemical Reactivity: The Role of the Frontier Orbitals on 1,3-Dipolar Cycloadditions. *J. Phys. Chem. A* **115**, 824–833 (2011).
38. La Porta, F. A., Santiago, R. T., Ramalho, T. C., Freitas, M. P. & Da Cunha, E. The role of the Frontier orbitals in acid–base chemistry of organic amines probed by ab initio and chemometric techniques. *Int. J. Quantum Chem.* **110**, 2015–2023 (2010).
39. Silva, R. R. da, Santos, J. M., Ramalho, T. C. & Figueroa-Villar, J. D. Concerning the FERMO concept and Pearson's Hard and Soft acid-base principle. *Braz. Chem. Soc.* **17**, 223–226 (2006).
40. Jin, Z. *et al.* Structure of M<sup><</sup>pro<sup>></sup>; from COVID-19 virus and discovery of its inhibitors. *bioRxiv* 02.26.964882 (2020) doi:10.1101/2020.02.26.964882.


41. Bickelhaupt, F. M. & Houk, K. N. Analyzing Reaction Rates with the Distortion/Interaction-Activation Strain Model. *Chemie Int. Ed.* **56**, 10070–10086 (2017).
42. Takezawa, H., Shitozawa, K. & Fujita, M. Enhanced reactivity of twisted amides inside a molecular cage. *Chem.* (2020) doi:10.1038/s41557-020-0455-y.
43. Zhou, L. *et al.* Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. *Med. Chem.* **49**, 3440–3443 (2006).
44. Yang, S. *et al.* Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. *Med. Chem.* **49**, 4971–4980 (2006).
45. Zhang, L. *et al.* Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved  $\alpha$ -ketoamide inhibitors. *Science (80-. ).* eabb3405 (2020) doi:10.1126/science.abb3405.
46. Cardoso Gajo, G., Rodrigues Silva, D., Barigye, S. J. & da Cunha, E. F. F. Multi-objective Optimization of Benzamide Derivatives as Rho Kinase Inhibitors. *Inform.* **37**, (2018).
47. Liu, J. *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* **6**, 16 (2020).
48. Paulekuhn, G. S., Dressman, J. B. & Saal, C. Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database. *Med. Chem.* **50**, 6665–6672 (2007).
49. Follmann, H. D. M. *et al.* Extent of shielding by counterions determines the bactericidal activity of N,N,N-trimethyl chitosan salts. *Polym.* **137**, 418–425 (2016).
50. Moulin, B. & Ponchon, T. A comparative review of use of sulphate and phosphate salts for colonoscopy preparations and their potential fornephrotoxicity. *Endosc. Int. open* **6**, E1206–E1213 (2018).
51. Gupta, D., Bhatia, D., Dave, V., Sutariya, V. & Varghese Gupta, S. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations. *Molecules* **23**, 1719 (2018).
52. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. Hratchian, J. V. Ort, W. C. Gaussian, Inc., Wallingford CT. (2009).
53. Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. *Protoc. Bioinforma.* **54**, 5.6.1-5.6.37 (2016).
54. Novoselov, K. P. *et al.* CHIMERA: A software tool for reaction rate calculations and kinetics and thermodynamics analysis. *Comput. Chem.* **23**, 1375–1389 (2002).
55. Accelrys Software. Discovery Studio Modeling Environment. (2012).
56. Scott, W. R. P. *et al.* The GROMOS Biomolecular Simulation Program *Phys. Chem. A* **103**, 3596–3607 (1999).
57. Deepa, G., Sivakumar, K. C. & Sajeevan, T. P. Molecular simulation and in vitro evaluation of chitosan nanoparticles as drug delivery systems for the controlled release of anticancer drug cytarabine against solid tumours. *3 Biotech* **8**, 493 (2018).
58. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics. *Mol. Graph.* **14**, (1996).

## Figures




**Figure 1**

Crystallographic structure of the Covid-19 virus Mpro enzyme with the co- crystallized ligand 6-(ethylamino)pyridine-3-carbonitrile (PDB code 5R82) (up),<sup>27</sup> and re-docking result of the co-crystallized ligand through AutoDock Vina28 as implemented in the MolAr software (down).<sup>29</sup>




**Figure 2**

Proposed mechanism for the synthesis of nitro derivative of quinoline and quinoline N-oxide




**Figure 3**

Optimised structures of nitro derivatives of (a) Q and (b) QO and computed electrostatic potential maps with contour value of 0.004.




**Figure 4**

Intermolecular interactions performed by the inhibitors (A) N-4-Q, (B) N-4-QO, (C) CQ, (D) CQO, (E) HCQ and (F) HCQO in the Mpro active site.



**Figure 5**

Overlap of the initial (blue) and representative (red) structures of the 10-ns simulation of MD.



**Figure 6**

Interactions performed during 10ns in the MD simulation with the (A) Mpro/N-4-Q, (B) Mpro/N-4-QO, (C) Mpro/CQ, (D) Mpro/CQO, (E) Mpro/HCQ, (F) Mpro/HCQO complexes.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SUPPLEMENTARY MATERIAL NitroDerivados.pdf](#)